The findings, published in the Journal of Experimental Medicine (JEM), indicate that activating an immune signaling pathway best known for fighting viral and bacterial infections could boost the ability of genetically engineered T cells to eradicate breast cancer in mice.
The study was led by Jonathan S Serody, the Elizabeth Thomas professor of medicine, microbiology, and immunology and director of the cellular therapy program at the University of North Carolina School of Medicine.
Chimeric antigen receptor (CAR) T-cells are a type of white blood cell that have been genetically engineered to recognize and attack cancer cells expressing specific proteins on their surface.
Chimeric antigen receptor (CAR) T-cells have been successfully used to treat patients with B cell lymphomas and are currently undergoing clinical trials for the treatment of many other types of blood cancer. But they may be less effective against solid tumors because they have to migrate into the tumors and then survive long enough to kill all of the tumor cells.
Moreover, the cells and molecules surrounding tumors are often immunosuppressive, activating an immune checkpoint that causes the CAR T-cells to lose their activity, said the team.
In the new study, Serody and colleagues tested several strategies to boost the effectiveness of CAR T-cells in a mouse model of breast cancer.
One strategy used was to simultaneously treat the mice with agonists, such as cGAMP, that activate the STING pathway, an immune cell signaling pathway that normally induces inflammation in response to invading viruses or bacteria.
"breast" - Google News
January 04, 2021 at 09:45PM
https://ift.tt/3b8FMjQ
Strategy identified to enhance activity of CAR T-cells against breast cancer - BioPharma-Reporter.com
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "Strategy identified to enhance activity of CAR T-cells against breast cancer - BioPharma-Reporter.com"
Post a Comment